Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 3. Rapid correction of low vitamin D status in nursing home residents 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study)
The American Journal of Cardiology, 06/22/09
Robinson JG et al. – Ezetimibe/simvastatin (E/S) is more likely to result in lipid treatment endpoints than atorvastatin and was generally well tolerated at the compared doses.
Methods- Double-blind, randomized, 6-week study of lipid-lowering efficacy of E/S 10/20 mg vs atorvastatin 10 or 20 mg, and E/S 10/40 mg vs atorvastatin 40 mg
- Subjects: 1,128 pts with hypercholesterolemia and the metabolic syndrome
- Primary endpoint: percentage of change from baseline in low-density lipoprotein (LDL) cholesterol
- Additional endpoints: changes in other lipids, lipoprotein ratios, high-sensitivity C-reactive protein, and attainment of pre-specified lipid levels
- Significantly greater improvements in levels of LDL cholesterol, non–high-density lipoprotein cholesterol, apolipoprotein B, and lipid/lipoprotein ratios with E/S vs atorvastatin at all dose comparisons
- Attainment of prespecified LDL cholesterol and non–high-density lipoprotein cholesterol levels significantly greater with E/S vs atorvastatin at all dose comparisons
- High-density lipoprotein cholesterol increases significantly greater with E/S 10/20 mg vs atorvastatin 10 mg and E/S 10/40 mg vs atorvastatin 40 mg
- Changes in triglycerides, very low-density lipoprotein cholesterol, and high-sensitivity C-reactive protein similar for both treatments
- Low incidence of liver, muscle, and gastrointestinal-, hepatitis- and allergic reaction/rash-related adverse events, generally similar to those in previous studies of E/S and/or atorvastatin
Today in Atherosclerosis/Lipids...keeping you current
Receive free subspecialty "5-minute updates" via email
Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia
Journal of Clinical Lipidology, 10/14/09
Prevalence of Unresponsiveness to Aspirin and/or Clopidogrel in Patients With Stable Coronary Heart Disease
The American Journal of Cardiology, 10/21/09
Cardiovascular diseases and risk of hip fracture
JAMA, 10/22/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial
Diabetic Medicine, 10/01/09
Safety and efficacy of testosterone gel in the treatment of male hypogonadism
Clinical Interventions in Aging, 10/12/09
Bisphosphonate therapy: When not to monitor BMD
The Journal of Family Practice, 11/02/09
Sponsor
Article Search
Sponsor


See Latest Articles


